Soluble CD30: A Possible Serum Tumor Marker for Primary Effusion Lymphoma
Soluble CD30: A Possible Serum Tumor Marker for Primary Effusion Lymphoma
复制标题
DOI：
10.7314/apjcp.2012.13.10.4939
复制
发表时间：
2012-01-01
影响因子：
--
通讯作者：
Okada, Seiji
中科院分区：
文献类型：
--
作者：
Michai, Manthana;Goto, Hiroki;Okada, Seiji
背景：已知可溶性CD 30（sCD 30）的血清水平在几种淋巴瘤中升高，并与预后相关。原发性渗出性淋巴瘤（PEL）是一种高度侵袭性、预后差的恶性淋巴瘤，但sCD 30在PEL中的存在及其意义尚未得到详细研究。目的：由于膜型CD 30经常在PEL细胞表面表达，我们比较了PEL细胞系以及其他淋巴瘤中膜型CD 30的表达和sCD 30的产生。方法：采用流式细胞术检测淋巴瘤细胞表面CD 30的表达，ELISA法检测sCD 30的表达。结果：PEL细胞系、霍奇金淋巴瘤细胞系和成人T细胞白血病/淋巴瘤细胞系表面和sCD 30均有表达。各细胞系表面CD 30和sCD 30水平具有相关性。结论：血清sCD 30水平可作为CD 30阳性的PEL的诊断和治疗的一个有用的生物学肿瘤标志物。
Background: The serum level of soluble CD30 (sCD30) is known to be increased with several lymphomas and to correlate with prognosis. Primary effusion lymphoma (PEL) is a highly aggressive malignant lymphoma with poor prognosis, but the existence and significance of sCD30 in PEL have not yet been investigated in detail. Objectives: Since the membrane type of CD30 is frequently expressed on the surface of PEL cells, we compared the expression of the membrane type of CD30 and the production of sCD30 among PEL cell lines as well as other lymphomas. Methods: The expression of surface CD30 in various lymphoma cell lines was analyzed with flow cytometry ans sCD30 was quantified by ELISA. Results: Both surface and sCD30 were detected on PEL cell lines as well as on Hodgkin's lymphoma and adult T-cell leukemia/lymphoma cell lines. Surface CD30 and sCD30 levels of each cell lines correlated with each other. Conclusion: The serum level of sCD30 appear to be a useful biological tumor marker for the diagnosis and management of CD30-positive PEL.